Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Sarcoma 1

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Advanced Endometrial Cancer × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Genmab

Phase 2 Withdrawn
Gynecologic

Advanced Endometrial Cancer

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Novartis

Phase 2 Completed
70 enrolled 8 charts
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡